MK-677 (Ibutamoren): An Oral Growth Hormone Secretagogue
MK-677 (ibutamoren mesylate) occupies a unique position in growth hormone research. Unlike peptide-based GH secretagogues such as ipamorelin, GHRP-2, and GHRP-6, MK-677 is a non-peptide, orally bioavailable small molecule that activates the ghrelin receptor (GHS-R1a) to stimulate endogenous growth hormone release. Developed by Merck Research Laboratories, it has a molecular weight of 528.67 Da and a half-life of approximately 24 hours, enabling once-daily oral dosing — a significant practical advantage over injectable peptide secretagogues that require multiple daily administrations.
This article provides a detailed comparison of MK-677 with injectable GH peptides, examining mechanisms, pharmacokinetic profiles, GH release patterns, selectivity, and research applications to help researchers select the optimal compound for their specific experimental questions.
Mechanism of Action
MK-677 is a potent, selective agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor activated by the endogenous hormone ghrelin and by synthetic peptide secretagogues. GHS-R1a is a class A GPCR expressed on anterior pituitary somatotroph cells, as well as in the hypothalamus (arcuate nucleus, ventromedial hypothalamus), hippocampus, and brainstem.
Upon binding to GHS-R1a on pituitary somatotrophs, MK-677 activates the Gq-phospholipase C (PLC)-inositol triphosphate (IP3)-calcium signaling cascade. IP3 triggers calcium release from intracellular stores, while concurrent activation of voltage-gated calcium channels increases cytoplasmic calcium concentration. This calcium signal stimulates the exocytosis of pre-formed GH-containing secretory granules. Additionally, MK-677 (like other GHS-R agonists) suppresses hypothalamic somatostatin (SRIF) release, removing the primary inhibitory brake on GH secretion and further amplifying the GH response.
Because MK-677 is a small molecule rather than a peptide, it has several pharmacological properties that differ from peptide-based secretagogues. It is orally bioavailable (absorbed intact from the gastrointestinal tract, unlike peptides which are degraded by digestive enzymes). It crosses the blood-brain barrier (BBB), allowing direct access to hypothalamic and other central GHS-R1a populations. And its 24-hour half-life produces sustained receptor occupancy rather than the transient engagement characteristic of short-acting peptides.
Comparison with Injectable Peptide Secretagogues
To contextualize MK-677, it is essential to compare it with the major injectable GH peptides, each of which has distinct properties relevant to research design.
Ipamorelin is a synthetic pentapeptide GHS-R1a agonist with a half-life of approximately 2 hours. It is the most selective of the peptide secretagogues: it stimulates GH release with minimal effects on cortisol, prolactin, or ACTH. This selectivity makes ipamorelin the preferred peptide when a 'clean' GH stimulus is needed without confounding hormonal changes. GH release peaks at 15–30 minutes post-injection and returns to baseline within 2–3 hours, producing a sharp physiological pulse. The short half-life necessitates 2–3 daily injections for sustained protocols.
GHRP-2 (Growth Hormone Releasing Peptide-2) is a hexapeptide with potent GH-releasing activity but lower selectivity than ipamorelin. It stimulates cortisol and prolactin release to a modest but measurable degree, and consistently increases appetite through hypothalamic ghrelin-like effects. Its half-life is approximately 15–30 minutes, requiring frequent dosing for sustained protocols. GHRP-2 is valued in research for its potent GH-stimulating activity when the additional hormonal effects are either desired as research endpoints or considered acceptable confounders.
GHRP-6 is the least selective of the common peptide secretagogues. It produces strong GH release accompanied by significant increases in cortisol, prolactin, and appetite. The pronounced appetite-stimulating effect (mediated through hypothalamic GHS-R1a activation) can be a confounding variable in metabolic studies but is itself a subject of research in appetite regulation. Half-life is approximately 15–30 minutes.
CJC-1295 (with or without DAC) acts through the GHRH receptor rather than GHS-R1a, making it mechanistically complementary to all GHS-R agonists including MK-677. CJC-1295 with DAC has a 6–8 day half-life due to covalent albumin binding, producing sustained GH axis stimulation. CJC-1295 without DAC (modified GRF 1-29) has a 30-minute half-life suitable for pulsatile protocols. Because CJC-1295 targets a different receptor, it can be combined with GHS-R agonists for synergistic GH release.
Key Differences: MK-677 vs Injectable Peptides
Route of administration. MK-677's oral bioavailability eliminates the need for injections, which is a significant practical advantage. In animal research, injection stress (handling, restraint, needle insertion) is a documented variable that can independently affect GH secretion, corticosterone levels, and behavioral endpoints. Oral dosing via drinking water or gavage may reduce this confound. In long-duration studies, oral dosing dramatically improves compliance and reduces the risk of injection site complications.
GH release profile. This is perhaps the most important pharmacological distinction. MK-677's 24-hour half-life produces sustained, relatively continuous elevation of GH and IGF-1 levels throughout the dosing interval. Injectable peptides with short half-lives (ipamorelin, GHRP-2, GHRP-6, modified GRF 1-29) produce acute GH pulses that peak and resolve within 2–3 hours. The physiological relevance of these different profiles is significant: endogenous GH is secreted in distinct pulses, and this pulsatile pattern is thought to be important for maintaining GH receptor sensitivity, appropriate IGF-1 regulation, and tissue-specific responses. Sustained GH elevation may produce different biological effects than pulsatile exposure, even at equivalent total GH exposure over 24 hours.
IGF-1 dynamics. MK-677 produces sustained IGF-1 elevation that mirrors its sustained GH profile. Injectable peptides produce transient IGF-1 increases that may not be captured by single time-point measurements. Published data show that MK-677 increases mean 24-hour IGF-1 levels by 40–90% depending on dose and study population.
Selectivity profile. Ipamorelin has the cleanest selectivity profile (GH release with minimal cortisol/prolactin stimulation). MK-677 occupies an intermediate position, with modest effects on cortisol that are generally considered clinically insignificant at standard doses. GHRP-6 has the broadest hormonal effects.
Appetite effects. MK-677 consistently increases appetite in published studies, an effect mediated through ghrelin-like hypothalamic signaling. This can be a confounding variable in metabolic research or a desired endpoint in appetite regulation studies. Among injectable peptides, GHRP-6 has the strongest appetite effects, while ipamorelin has minimal impact on appetite.
Published Research Applications
MK-677 has been evaluated in multiple published studies across several research domains. Age-related GH decline: oral MK-677 restored GH pulsatility and IGF-1 levels in elderly subjects to young-adult ranges. Body composition: sustained GH/IGF-1 elevation produced measurable changes in lean mass and fat mass in multiple study populations. Bone density: long-term MK-677 administration increased bone mineral density markers and osteoblast activity markers in postmenopausal women. Sleep architecture: MK-677 increased stage IV (deep) sleep duration by approximately 50% and REM sleep duration by approximately 20%, likely through hypothalamic GHS-R1a effects on sleep-regulating circuits.
Practical Research Notes
MK-677 is available from MiPeptidos as lyophilized powder at 99%+ HPLC purity. As a non-peptide small molecule, it is highly stable and can be dissolved in water for oral administration or reconstituted with BAC water for research protocols. Store lyophilized at -20°C. Its oral bioavailability and long half-life make it particularly suitable for chronic administration studies where daily injection protocols would be impractical.
Disclaimer
For research purposes only. Not for human consumption.